Cabaletta Bio, Inc. (Nasdaq: CABA), a cutting-edge biotechnology company developing targeted, curative cell therapies for patients with autoimmune diseases, is pleased to welcome Shawn Tomasello to its Board of Directors.
With extensive experience in the life sciences industry and deeper knowledge of CD19-CAR T technology, Ms. Tomasello comes to Cabaletta with a wealth of industry knowledge, having recently served as Chief Commercial Officer of Kite Pharma, Inc. throughout the commercialization process of the life-changing CD19-CAR T cell therapy, Yescarta®, and its acquisition by Gilead Sciences, Inc. In her role at Cabaletta, Ms. Tomasello will join the Compensation Committee and the newly established Science & Technology Committee.
Cabaletta is pleased to welcome Shawn Angus to its Board of Directors, drawing on his extensive background in biopharmaceutical leadership to bring its transformative therapy, CABA-201, closer to commercialization.
Angus has previously overseen the global launch of the leading approved CD19-CAR T cell therapy and has in-depth experience coordinating pre-launch activities, scaling and commercializing therapies. CEO and Co-founder Steven Nichtberger, M.D., believes Angus’ expertise will be a tremendous asset to Cabaletta’s future development and success.
Ms. Tomasello is a highly experienced life sciences professional, bringing more than three decades of expertise to her role. She was recently the Chief Commercial Officer at Kite Pharma, now a part of Gilead Sciences, where she spearheaded the global commercialization of Yescarta®, the first approved CAR-T therapy for non-Hodgkin lymphoma.
Before this, Ms. Tomasello held senior leadership roles at Celgene Corporation, where she led the company through five successful product launches. In addition, she was National Director of Hematology for Rituxan® at Genentech, Inc. Beforehand, she held positions at Pfizer Laboratories, Miles Pharmaceuticals, Inc. and Proctor & Gamble Company. Ms. Tomasello holds an M.B.A. from Murray State University and a B.S. in Marketing from the University of Cincinnati.
I am thrilled to be joining Cabaletta’s Board of Directors and to help unlock the potential of its life-changing, targeted cell therapies for autoimmune diseases. With my extensive experience in the life sciences industry, I am eager to bring CABA-201 to patients in need and contribute to the continued success and advancement of Cabaletta’s pioneering CABA™ platform.
About Cabaletta Bio
At Cabaletta Bio (Nasdaq: CABA), the mission is clear: to provide potentially curative therapies for patients with autoimmune diseases. To make this dream a reality, the cutting-edge biotechnology company has developed the CABA™ platform, which encompasses two strategies to combat these illnesses. CARTA, the chimeric antigen receptor T cell strategy, can target systemic lupus erythematosus and myositis and is currently led by the fully human CD19-CAR T, CABA-201.
For mucosal pemphigus vulgaris and MuSK myasthenia gravis, CAART, the chimeric autoantibody receptor T cell strategy, is being explored with multiple clinical-stage candidates. Headquartered in Philadelphia, Cabaletta Bio is dedicated to discovering and developing engineered T cell therapies that could provide durable and potentially life-saving treatments for autoimmune disease sufferers.